On September 25, 2026 CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), reported that management will host a conference call and webcast on Wednesday, September 30, 2026, at 8:30 a.m. Eastern Time to provide a business update on CNSide, the Company’s cerebrospinal fluid (CSF) diagnostic platform, offered through its wholly owned subsidiary, CNSide Diagnostics, LLC. The update will focus on recent commercial related developments including third-party billing, market access, expansion of the commercial team and broadening of the diagnostic testing portfolio.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Our CNSide Diagnostics team has made tremendous progress since we launched CNSide in early 2026," said Marc H. Hedrick, M.D., Cerenome’s President and Chief Executive Officer. "We would like to provide our stockholders and the broader capital markets community the opportunity to learn more about positive recent developments, progress to 2026 goals and plans to grow and expand the business."
Conference Call and Webcast
Date Wednesday, September 30, 2026
Time 8:30 a.m. Eastern Time
Webcast Click here to access the webcast
Dial-in (U.S./Canada) 877-270-2148
Dial-in (International) 412-902-6510
A replay of the webcast will be available following the conclusion of the event in the Investor Relations section of the Company’s website at www.cerenome.com.
(Press release, Cerenome, SEP 25, 2026, View Source [SID1234671091])